Literature DB >> 29490416

An eleven-year retrospective cross-sectional study on pulmonary alveolar proteinosis.

Arda Kiani, Tahereh Parsa, Parisa Adimi Naghan, Hervé Dutau, Fatemeh Razavi, Behrooz Farzanegan, Mahsa Pourabdollah Tootkaboni, Atefeh Abedini1.   

Abstract

INTRODUCTION: Pulmonary alveolar proteinosis (PAP) is a rare disease in the field of pulmonary medicine. The efficacy of whole-lung lavage (WLL) as the treatment of PAP had never been evaluated in the Iranian population. Therefore, there is a real need to investigate the characteristics of PAP and also to evaluate the efficacy of WLL in this rare disease. The study aimed to investigate demographic features, clinical presentation and treatment outcomes of the disease in Iranian PAP patients.
MATERIAL AND METHODS: Data of 45 patients with definite diagnosis of PAP, who had regular follow-ups from March 2004 to March 2015 at an Iranian referral respiratory hospital, were collected. Whole-lung lavages (WLL) efficacy was assessed by comparing spirometric, arterial blood gas parameters and six-minute walk test (6MWT) results before and after all lavages.
RESULTS: Mean age at diagnosis of disease was 30.33 ± 14.56 years. Four patients (8.8%) reported non-massive hemoptysis and three subjects (6.6%) had concomitant pulmonary tuberculosis. In 71.1% of cases, transbronchial lung biopsy and bronchoalveolar lavage were sufficient for diagnosis. Spirometric results and arterial blood gas parameters and 6MWD improved significantly after all the lavages. Four patients (8.8%) died because of respiratory failure. The only variable capable of predicting treatment failure was the history of hemoptysis.
CONCLUSION: The study revealed sufficiency of WLL as the PAP patients' treatment. Also hemoptysis was found to be the independent factor that can predict treatment failure.

Entities:  

Keywords:  bronchoalveolar lavage (D018893); pulmonary alveolar proteinosis (D011649); whole-lung lavage

Mesh:

Year:  2018        PMID: 29490416     DOI: 10.5603/ARM.2018.0003

Source DB:  PubMed          Journal:  Adv Respir Med        ISSN: 2451-4934


  3 in total

1.  Pulmonary Alveolar Proteinosis Due to Pneumocystis carinii in Type 1 Hyper-IgM Syndrome: A Case Report.

Authors:  Fei Zhou Zhang; Jie Xin Yuan; Lu Qin; Lan Fang Tang
Journal:  Front Pediatr       Date:  2020-06-11       Impact factor: 3.418

2.  Alveolar Proteinosis Secondary to M. tuberculosis, in a Patient with Transient CD4 Lymphocytopenia Due to Cryptococcus neoformans Infection: First Case in the Literature.

Authors:  Daniel Augusto Martin Arsanios; Diego Alejandro Cubides-Díaz; Natalia Muñoz-Angulo; Maria Alejandra Perez-Hernandez; Marlyn Zamora Posada; Mónica Briceño Torres; Carlos Mauricio Calderón Vargas
Journal:  Infect Dis Rep       Date:  2022-03-04

3.  Complete remission of pulmonary alveolar proteinosis after anti-tuberculous chemotherapy: a case report.

Authors:  Guangtao Fan; Yilong Huang; Fenglin Xue; Bo He
Journal:  J Int Med Res       Date:  2022-07       Impact factor: 1.573

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.